End-stage Renal Disease Therapeutics

End-stage renal disease (ESRD) requires kidney replacement therapy or, for eligible patients, transplantation. Therapeutic management combines dialysis, transplantation, anemia treatment, mineral and bone disorder control, cardiovascular risk reduction, infection prevention, and symptom management. The clinical burden is shaped by diabetes, hypertension, aging, cardiovascular disease, and unequal access to nephrology care and dialysis infrastructure. Treatment decisions depend on residual kidney function, comorbidities, transplant suitability, patient preferences, local clinical guidance, and affordability.

The ESRD treatment landscape is moving from reactive dialysis initiation toward earlier chronic kidney disease detection, structured preparation for kidney replacement therapy, and shared decision-making. Greater attention is being given to arteriovenous access, peritoneal dialysis, home hemodialysis, conservative kidney management, and timely transplant evaluation. Quality priorities increasingly include vascular-access preservation, infection prevention, medication safety, treatment adherence, functional status, and patient-reported outcomes. Persistent barriers include late referral, workforce shortages, reimbursement complexity, infrastructure gaps, and uneven availability of transplant services.

Artificial intelligence can support ESRD care by identifying patients at risk of progression, hospitalization, treatment complications, access failure, and missed appointments. It may also help interpret laboratory trends, optimize dialysis scheduling, monitor devices, and reduce administrative workload. However, clinical value depends on representative data, external validation, transparent performance evaluation, cybersecurity, privacy protection, and integration into clinician workflows. Models must be monitored for bias affecting patients with limited access, multiple comorbidities, or underrepresented demographic and geographic characteristics; AI should augment rather than replace clinical judgment.

North America generally has extensive dialysis capacity and specialist services, but faces high chronic disease burden, access disparities, and affordability pressures. Europe benefits from established nephrology networks, national or regional quality frameworks, and broader use of home therapies in some systems, while treatment access and reimbursement remain heterogeneous. Asia-Pacific combines advanced transplant and dialysis programs in some economies with major rural-access and affordability constraints elsewhere. Latin America continues to address uneven dialysis availability, late diagnosis, and dependence on public financing. The Middle East is expanding specialist and transplant capacity while managing diabetes, hypertension, and workforce needs. Africa faces the most pronounced infrastructure, workforce, affordability, and continuity-of-care barriers, making prevention, early detection, and scalable treatment models especially important.

ASEAN countries show wide variation in dialysis coverage, insurance protection, transplant infrastructure, and rural access, creating a strong need for adaptable care pathways. BRICS members span sophisticated tertiary systems and substantial unmet need, with affordability and geographic inequity recurring concerns. The European Union supports cross-border policy coordination and clinical standardization, although national reimbursement and service capacity differ. G7 health systems generally possess strong specialist infrastructure but continue to manage aging populations, multimorbidity, workforce pressure, and inequitable outcomes. GCC countries have invested in advanced healthcare capacity while confronting high diabetes prevalence and demand for specialized renal services. NATO members encompass diverse health systems, and resilience planning increasingly includes continuity of dialysis during emergencies, displacement, and infrastructure disruption.

Australia emphasizes integrated chronic disease management, rural and remote access, home dialysis, and transplantation. Brazil continues to address regional disparities and public-system capacity. Canada focuses on equitable access across large geographic areas, home therapies, and Indigenous health needs. China is expanding chronic kidney disease detection and treatment capacity while managing substantial regional variation. France, Germany, Italy, Spain, and the United Kingdom maintain established specialist systems but face aging-related demand, workforce constraints, and pressure to improve home therapy and transplant pathways. India is prioritizing earlier detection, affordability, and broader dialysis access. Japan and South Korea combine advanced clinical capabilities with aging-population pressures and long-term care coordination needs. Mexico faces gaps in early diagnosis, financing, and geographic access. Russia must maintain continuity of specialist care across a large territory and varied regional capacity. The United States has extensive treatment capability but continues to confront disparities, cost pressures, vascular-access challenges, and unequal transplant access.

Leaders should align product development and service design with patient-centered pathways spanning advanced chronic kidney disease, dialysis, transplantation, and conservative care. Priorities include therapies that reduce treatment burden, strengthen anemia and mineral-bone disorder management, lower infection and access complications, and support home-based care. Organizations should build evidence around meaningful clinical and patient-reported outcomes, conduct subgroup analyses, and demonstrate value across different health-system settings. Partnerships with providers, payers, regulators, patient organizations, and local workforces can improve implementation. Responsible AI programs should use rigorous validation, human oversight, clear accountability, and continuous monitoring. Equitable access should be treated as a core performance objective through affordability planning, training, supply continuity, and solutions suitable for rural and resource-constrained settings.

This executive summary uses a structured review approach focused on verified information from established clinical guidelines, peer-reviewed literature, public health agencies, regulatory materials, transplant and dialysis registries, and official national or regional health-system sources. Evidence was synthesized thematically across treatment modalities, complications, care delivery, digital health, geography, and population groups. Regional, group, and country observations were compared qualitatively according to documented differences in disease burden, infrastructure, reimbursement, workforce, transplant capacity, and access. Claims were limited to recurring, supportable findings; no market estimates, market shares, forecasts, or unsupported commercial assertions were used.

ESRD therapeutics will advance most effectively when clinical innovation is paired with prevention, timely referral, resilient delivery systems, and patient choice. The central opportunities are to delay progression where possible, prepare patients before kidney replacement therapy, expand safe home and transplant pathways, improve complication management, and reduce geographic and socioeconomic inequities. Decision-makers should evaluate therapies and technologies not only by biological efficacy, but also by usability, continuity, affordability, safety, and real-world outcomes. Sustained collaboration across clinicians, patients, payers, regulators, and health systems is essential to translate innovation into dependable renal care.